The Italian Medicines Agency, AIFA, is enhancing its scientific and regulatory activities by establishing six new advisory committees covering major therapeutic areas.
The committees will contribute to the work of the agency’s technical scientific commission (CTS) and its pricing and reimbursement committee (CPR) by carrying out evaluations and providing opinions on regulatory and scientific matters.
Conflicts of interest considered
AIFA notes that it has followed conflict-of-interest rules in establishing the committees, which will each be comprised of seven members (maximum) who are leading clinical experts in their fields. The therapeutic areas are:
- Primary care
To contain costs and streamline procedures, the committees will generally hold their meetings via video conference; only on occasions of particular importance will meetings take place at AIFA headquarters.